Dataset:30708281 Search Result
Clinical information
Baseline characteristics of patients with PCR proven community acquired RSV included in this study (n = 44), divided by community acquired RSV A positive
patients with the new cluster of mutations (n = 10), other community acquired RSV A positive patients (n = 18) and community acquired RSV B positive patients
(n = 16).
Characteristics	RSV A mutated (n =10)	RSV A non-mutated (n =18)	RSV B (n =16)	p-value
Age (years)– median (IQR)	67.0 (37.4–74.3)	53.3 (25.1–62.6)*	63.1 (58.8–68.8)*	0.048
Male sex - no. (%)	5 (50%)	10 (56%)	7 (44%)	0.791
(Ex-)smoker- no. (%)	4 (40%)	9 (50%)	7 (44%)	0.861
Comorbidities
Immunocompromised - no. (%)	6 (60%)	13 (72%)	12 (75%)	0.765
Diabetes - no. (%)	4 (40%)	3 (17%)	2 (13%)	0.275
Asthma or COPD - no. (%)	3 (30%)	3 (17%)	4 (25%)	0.729
Chronic renal failure or hearth failure - no. (%)	7 (70%)*	4 (22%)*	5 (31%)
Current hematologic malignancy - no. (%)	2 (20%)	5 (28%)	1 (6%)	0.32
Diagnostic fi ndings at presentation
Symptom duration (days) - median (IQR)	3.0 (2.0-6.3)	3.0 (1.0-5.5)	4.5 (2.3-7.0)	0.731
Symptoms at presentation:	10 (100%)	17 (94%)	14 (88%)	0.598
Cough - no. (%)	10 (100%)	17 (94%)	14 (88%)	0.598
Dyspnoea - no. (%)	10 (100%)	12 (67%)	15 (94%)	0.042
Delirium - no. (%)	3 (30%)	3 (17%)	1 (6%)	0.337
Temperature (⁰C) - median (IQR)	37.9 (36.7–38.6)	38.2 (37.7–38.5)	37.4 (36.5–38.3)	0.252
Fever (temperature ≥ 38.0⁰C) - no. (%)	4 (40%)	10 (56%)	5 (31%)	0.312
CRP (mg/ L)- median (IQR)	68.5 (18.3–171.0)*	24.5 (11.3–58.2)*	24.0 (11.8–56.3)	0.126
Leukocytes (x10^9/ L)- median (IQR)	9.1 (6.1–11.7)	9.3 (5.3–12.1)	8.7 (6.1–10.9)	0.813
Disease severity and clinical outcomes
PaO2 (mmHg)- median (IQR)	61.0 (51.5–74.5)	68.0 (59.0–78.0)	66.0 (60.0–72.0)	0.436
O2-suppletion needed (≥ 1 L) - no. (%)	8 (80%)*	5 (28%)*	10 (63%)	0.02
CURB-65 score** - median (IQR)	1.5 (0.8–3.0)*	0.0 (0.0–2.0)	0.5 (0.0–1.0)*	0.079
Diagnosis RTI at presentation - no. (%)	8 (80%)	14 (78%)	15 (94%)	0.439
Pneumonia based on X-ray - no. (%)	6 (60%)	7 (39%)	5 (31%)	0.419
Length of hospital stay (days) - median (IQR)	3.5 (1.5–8.8)	0.0 (0.0–9.5)	6.0 (0.0–11.5)	0.933
In-hospital death - no. (%)	3 (30%)	1 (6%)	0 (0%)	0.045
Treatment started at presentation
Hospital admission - no. (%)	8 (80%)	8 (44%)	11 (69%)	0.155
Directly admitted to ICU or MCU - no. (%)	1 (10%)	3 (17%)	2 (13%)	1
Aerogenic isolation measurements - no. (%)	4 (40%)	5 (28%)	7 (44%)	0.665
Antibiotics - no. (%)	6 (60%)	13 (72%)	8 (50%)	0.453
Oseltamivir - no. (%)	4 (40%)	7 (39%)	4 (25%)	0.713
COPD, Chronic Obstructive Pulmonary Disease; CRP, C-reactive protein; CURB-65, confusion, urea, respiratory rate, blood pressure, age > 65 years; ED, emergency
department; MCU, Medium Care Unit; ICU, Intensive Care Unit; IQR, interquartile range; no., number; O2, oxygen; pO2, partial pressure of oxygen measured in
arterial blood sample; RTI, respiratory tract infection.
Substituted RSV-A, non-substituted RSV-A and RSV-B positive patients with community acquired RSV infection (n = 44) were compared by performing an one-way
ANOVA test for continuous variables and a chi square test or Fisher’s exact test for categorical variables. In case of overall significance, a post-hoc analysis was done
using Fisher LSD for continuous variables and using chi-square test for two groups for categorical variables. Significant differences between two groups as assessed by
post-hoc test is indicated with *. ** CURB-65 score consists of 5 items. 1 point is given per positive item: confusion, urea > 7 mmol/ L, respiratory rate ≥ 30 per
minute, systolic blood pressure < 90 mmHg or diastolic blood pressure ≤ 60 mmHg and age ≥ 65 years.